

# Index

## A

- Acquired drug resistance, 3
- Adherence, 131, 135, **174-179**, 194, 197, 204, 209
- DOT*, 13, 19, 36, 47, 50, 51, 100, 104, 114, **130**, 148, 172, **174**, 182, 195, 197, 198, 209, 245
- Incentives and enablers*, 116, 174, **178-179**, 198
- Legal orders*, 174, **179**, 195-198
- Patient education*, 131, 172, 174, **176-177**, 198, 243
- Psycho/social needs of patients*, 99, 100, 159, 172, **174-175**
- Adverse reactions, 53, 59-93, 133, **145-169**, 174, 246, 247, 250
- Central nervous system (CNS) toxicity*, ix, 66, 67, 75, 133, 136, **159-161**, 240
- Dermatologic and hypersensitivity*, 60, 64, 67, 75, 86, 89, 91, 93, **134**, **151-154**, **156-157**
- Desensitization*, **153-154**, 157
- Drug rechallenge doses*, **153-4**
- Gastrointestinal*, 60, 64, 70, 72, 75, 79, 80, 82, 84, 86, 91, 100, 134, **147-151**, 161
- Hepatotoxicity*, 70, 75, 82, 84, 86, 89, 91, 134, **150-151**
- Hematologic abnormalities*, 80, 84, 89, 91, **155**
- Hypothyroidism / endocrine effects*, 47, 70, 71, 84, 133, 134, 152, 158, 160, 166, **167**, **168**
- Musculoskeletal*, 75, 79, 82, 86, 89, 134, **166-167**
- Nephrotoxicity*, 59, 63, 77, 93, **165-166**
- Neurotoxicity*, 67, 70, 72, 75, 77, 79, 80, 82, 93, 106, 133, 134, 136, **158-164**
- Ophthalmic toxicity*, ix, 37, 45, 68, 75, 80, 81, 89, 104, 117, 134, 143, 151, **163-164**
- Ototoxicity*, ix, 38, 59, 63, 77, 93, 105, 118, 134, 143, 146, **162-163**, **246**
- Rifampin hypersensitivity*, **157**
- Stevens-Johnson syndrome*, 67, 154, 156
- Alopecia, 70, **168**
- Amikacin, vii, ix, 4, 22, 24, 35, 36, 39, 44, 46, 52, **58-59**, 62, 76-77, 93, 105-106, 109, 121, 153, 155, 182, 233, 240, 246, 248-249, 252, 254-255, 259
- Amoxicillin/clavulanate, 35, 38, 39, 45, **60-61**, 189, 244
- Anti-retroviral therapy (ART), 88, 90, **99-100**, 150
- Arthralgia, 75, 79, 82, 86-87, 89, 118, 159, **166-167**, 209

## Auditory **143**

*Monitoring*, 38, 59, 63, 77, 93, 105, 118, 129, 133, 143, 162, 163

*Toxicity*, 59, 77, 93, 134, 146, **162-163**

Azithromycin, **45**, 228, 240

## B

bacille Calmette-Guérin (BCG), 111, 202-205, 247, 255

BACTEC 460TB method, 233, 236, **238**

Breastfeeding, 59-93, **110**

Bronchoalveolar lavage (BAL), 113

Broth method, 26, 223, 232, **238-239**, 261

## C

Calcium, 133, 161, 165, 166

Capreomycin, vii, ix, 4, 22, 24, 35, 36, 38, 39, 43, 44, 46, 52, 58, **62-63**, 76, 105, 106, 109, 118, 121, 133, 134, 153, 159, 162, 165, 189, 233, 240, 246, 249

Care plan, 129, **140**, 180

Case management, 171-190

*Care plan*, 129, **140**, 180

*Contact investigation*, 28, 178, **186-187**, 203-204, 248

*Continuity of care*, 182-183

*Cultural barriers*, 174, 175-176

*Drug-O-Gram*, 129, **139**, 180

*Drug supply*, 13, **188**

*Infection control*, 177, **183-185**, 247

*Psycho/social needs*, 174-175

Central Nervous System (CNS) TB (see Extrapulmonary TB)

Central Nervous System (CNS) toxicity, ix, 66, 67, 75, 79, 82, 106, **159-162**, 240

*Depression*, 67, 131, **159-160**, 247, 252

*Psychosis*, 67, 131, **160**

*Seizures*, 72, **161**

*Suicidal ideation*, 67, 131, 159, **160**, 247

Cerebrospinal fluid (CSF), 59-93, **97**, 222

Chest X-ray (see Radiograph, Chest)

Children (see Pediatrics)

Clarithromycin, 45, 168, 241, 254-255

Clofazimine, 35, 39, 45-46, **64-65**, 133-134, 140, 151-152, 155, 163-164, 189, 241, 254-255

Color discrimination, 69, 104, 133, 140, 164

Computed tomography (CT), 96, 137, 140, 252

Congenital TB, **110-111**

Contact investigation, 28, 178, **186-187**, 203-204, 220, 248, 255, 257

Contacts, managing, x, 32, 51-52, 186-187, **201-211**, 250

*Duration of therapy*, 207

*Follow-up*, 210

*Importance of treating LTBI*, 204

*MDR-LTBI treatment options*, 207-208

*Principles for providing care*, 204-205

*Treatment of child contacts*, 209-210

*Treatment options*, 51-52, 206-208

*Treatment variable to consider*, 205-206

*Window prophylaxis*, 210

Corticosteroid, 96, 154, 156-157, 164, 206

Creatinine clearance, 104, 106, 133, 140, 164, 165

Critical concentrations, 25, 26, 27, 232, **233**, 237

Cross-resistance, 33, 36, 45, **46**, 58, 62, 76, 78, 82, 90, 92

Cultural barriers, 174, **175-176**

CureTB, 3, 20, 182, 187, 220

Cycloserine, ix, 35, 37, 39, 44, 46, 47, 48, 52, **66-67**, 97, 102, 105, 106, 109, 110, 111, 117, 121, 131, 133, 134, 1136, 150, 152, 153, 155, 156, 158, 159, 160, 161, 162, 165, 189, 206, 209, 233, 240, 241, 245, 247, 248, 249, 252, 255, 259

## D

Depression, 47, 67, 131, **159-160**, 247, 252

Dermatologic and hypersensitivity reactions, 60, 64, 67, 75, 86, 89, 91, 93, **134**, **151-154**, **156-157**

*Cutaneous fungal infections*, 168

*Desensitization*, **153-154**, 157

*Drug rechallenge doses*, **153-4**

*Flushing reactions*, **152**

*Hives, urticaria*, 151, **152-153**, 156

*Lichenoid drug reactions*, 67, **152**

*Maculopapular rash*, **151-152**

*Phototoxicity*, 64, 79, 87, 95, 151, **152**

*Pruritus*, 64, 91, **151-152**, 156

*Stevens-Johnson syndrome*, 67, 154, 156

Desensitization (see Dermatologic and Hypersensitivity Reactions)

Diagnosis of drug-resistant TB, **17-30**

*Laboratory (see Laboratory Diagnosis)*

*Questions to ask patients to assess risk*, 20-21

*Risk assessment*, 18-19

*Risk factors, in persons with history of TB*, 19

*Risk factors, in persons without history of TB*, 19

Diagnosis of latent TB infection (LTBI), 202-204

Dialysis, 58-93, **104-106**  
*Peritoneal dialysis*, **104-106**

Diarrhea, 60, 72, 75, 80, 82, 100, 130, 148, **149**, 156, 161, 165

Direct method, 23, 26, **232**, 236

Directly observed therapy (DOT), 13, 19, 36, 47, 50, 51, 100, 104, 114, 129, **130**, 148, 172, 173, **174**, 177, 178, 182, 195, 197, 198, 209, 245

Disseminated intravascular coagulation, 155, 157

Diuretic, 59, 77, 93, 163

Dizziness, 79, 82, 133, 134, 162-163

Drug absorption, 50, 51, 59-93, 96, 99, 100, 106, 118, **130**, 131, 132, 135, 148, 181, 240, 241

Drug administration, 116, **130**

Drug interactions, 88, 89, 91, 96, **99**, **100**, 104, **130**, 161, 244

Drug levels and monitoring (see Therapeutic Drug Monitoring)

Drug-O-Gram, 129, **139**, 140, 180

Drug ramping (see Treatment – Escalation of Dosages)

Drug reactions (see Adverse Reactions and Monitoring Patients)

Drug storage, 59-93, **188**

Drug supply / shortages, 13, **188**

## E

Education – patient, 131, 172, 174, **176-179**, 182, 198, 243

Electrolyte loss, 44, 59, 63, 84, 93, 148, 158, 161, **165-166**

Enablers, 174, 178, **179**, 198

Eosinophilia, **155**, 156

Epidemiology, 5-9

Ethambutol, 10, 11, 12, 24, 33, 35, 39, 43, 46, **68-69**, 97, 102, 104, 106, 117, 120, 134, 150, 153, 154, 155, 156, 158, 206, 207, 223, 238, 239, 240, 241, 249

Ethical issues, 194-195

Ethionamide, 12, 24, 35, 37, 39, 44, 46, 47, 48, 52, 66, **70-71**, 84, 97, 102, 106, 109, 110, 111, 116, 117, 121, 133, 134, 147, 152, 153, 155, 158, 159, 160, 162, 163, 164, 166, 167, 168, 189, 206, 207, 209, 233, 241, 245, 249

Expanded empiric treatment regimen, 32, 50, **52**, 254, 259

Expert consultation, 25, 35, 39, 45, 47, 49, **53**, 100, 108, 110, 111, 114, 146, 149, 160, 163, 172, 177, 180, 183, 185, 247

Expert resources, **214-219**

Extrapulmonary TB, 49, **96-98**, 99, 100, 114, 136  
*meningitis and CNS*, **96-98**, 99, 113, 114, 160, 222

Extremely drug-resistant TB (XDR), vii, **4**, 5, 6, 7, 9, 22, **39**, 189, 251-253

## F

False-positive results, **24**, 28, 234

Fluoroquinolones, 12, 35, 38, 44, 46, **78-79**, **82-83**, 102, 109, 117, 118, 134, 149, 158, 166, 168, 188, 209, 245  
*Use of in children*, 78, 82, **117-118**, **209**, 245

Flushing, **152**

Foreign-born persons (see Immigrants)

Fungal infection, **168**

## G

Gamma-interferon, 155, 244

Gastric aspirates, 111, 113-114, 136

Gastrointestinal side effects, 60, 64, 70, 72, 75, 79, 80, 82, 84, 86, 91, 100, 134, **147-151**, **161**

Genotyping, 3, **28**, 224, 231  
*CDC genotyping program*, 28

Green Light Committee, 220

Gynecomastia, 70, **168**

## H

Hearing loss, ix, 59, 63, 77, 93, 105, 118, 134, 143, 146, **162-163**, **246**

Hematologic abnormalities, 80, 84, 89, 91, **155**

Hemolytic anemia, 91, 155, 157

Hepatitis B & C, 150-151

Hepatotoxicity, 70, 75, 82, 84, 86, 89, 91, 134, **150-151**  
*See also Adverse Reactions, GI*

HIV, 4, 13, 41, 43, 51, 88, 90, 96, 97, 98, **99-101**, 109, 128, 130, 132, 150, 152, 158, 164, 177, 183, 189, 204, 206, 207, 208, 210

Hives (see Dermatologic and Hypersensitivity Reactions)

Hypersensitivity reaction, 60, 75, **152-154**, **156-157**

Hypothyroidism, 47, 70, 71, 84, 133, 134, 152, 158, 160, 166, **167**

## I

Imipenem, 35, 38, 39, 45, 57, 60, **72-73**, 155, 189, 244

Immigrants, 5, 7, **9**, 19, 175, 187, 203, 204

Incentives, 116, 174, 178-**179**, 198

Indirect method, 26, 232, 236, **237**

Infection control, 4, 7, 22, **110**, 135, 177, **183-186**, 197, 247

Injectable drugs, ix, 4  
*See also Amikacin, Capreomycin, Kanamycin and Streptomycin*

Interferon gamma release assay (IGRA) viii, 22, 51, **202-204**, 206, 207, 208

International organizations, 2, **220**

International Union Against TB and Lung Disease (IUATLD), 109, **220**

International resources, 20, **221**  
*International Standards for Tuberculosis Care (ISTC)*, 2, 221

Intramuscular, 44, 58, 59, 62, 74, 76, 92, 118, 246

Intraperitoneal, 58, 92, 105

Intrathecal, 58, 92, 98

Intravenous, 38, 45, 47, 58, 62, 74, 76, 78, 80, 90, 92, 240

Isolation, discontinuation of, **184-185**

Isoniazid (INH), vii, 2, 4, 5, 7, 9, 10, 11, 12, 13, 22, 24, 25, 26, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 46, 49, 51, 52, **74-75**, 97, 98, 102, 106, 107, 108, 109, 110, 111, 119, 131, 132, 134, 136, 148, 152, 153, 154, 155, 156, 158, 160, 161, 162, 163, 166, 168, 202, 204, 205, 206, 208, 209, 210, 223, 233, 234, 236, 237, 238, 239, 241, 249, 259

## K

Kanamycin, vii, 4, 22, 24, 35, 36, 39, 44, 46, 58, 59, 62, 63, **76-77**, 93, 105, 106, 109, 121, 155, 233, 240, 242, 246, 251

## L

Laboratory diagnosis  
*False-positive results*, **24**, 27, 234  
*National standards for lab turnaround times*, 23  
*Strain typing*, **28**, 224, 226, 228, 231  
*Susceptibility testing, interpretation*, **25**, 233, 236-239  
*Susceptibility testing, methods*, 26-27, **232-239**  
*Variation in results*, 27

Laboratory diagnosis, susceptibility testing  
*BACTEC 460TB Method*, 26, **238**  
*Direct Method*, 26, **232**  
*Indirect Method*, 26, **237**  
*Molecular Methods*, 27, **234-235**  
*Newer Broth Methods*, 26, **239**  
*Proportion Method*, 26, **236**

Laboratory resources, **222-231**

Lactation, 59-93, **110**, 111

Latent tuberculosis infection (LTBI), x, 176, 184-187, **202-209**

Legal orders, 174, **179**, 195-198

Leukopenia, 80, 89, **155**, 157, 169

Levofloxacin, 35, **78-79**, 102, 106, 155, 189, 241  
*See also Fluoroquinolones*

Linezolid, 35, 38, 39, 45, **80-81**, 134, 155, 158, 159, 161, 162, 163, 164, 189, 241, 244, 252

Liver disease, 59-93, **102-103**, 150

See also *Hepatotoxicity*

Liver function tests (LFTs), 133, 150

Lupus / lupoid reactions, 75, 157

## M

Macrolide, 35, 38, 39, 45, 100, 168, 188

Magnesium, 59, 63, 78, 82, 13, 161, 165, 166

Malabsorption, 50, 51, 96, 99, 100, 240

Médecins Sans Frontières, 220

Medication Fact Sheets, 57-94

Mental health, 100, **131**, 175, 247

Metallic taste, 168

Minimum inhibitory concentration (MIC), 25, 136

Monitoring patients

*Common side effects*, 58-93, **132-133**, 143

*Documentation*, **129**, 139-143

*Drug absorption and drug interactions*, 100, **130**

*Drug administration*, 116, **130**

*Drug toxicity*, 58-93, **132-133**, 143

*General monitoring*, 129

*Initial evaluation*, 128

*Microbiologic monitoring*, **135-136**, 139, 142

*Radiographs*, 137

*Respiratory symptoms*, 132

*Substance abuse, mental health*, 131

*Systemic symptoms*, 132

*Toxicity monitoring*, 58-93, **132-133**, 143

*Therapeutic drug levels*, 136, 240-242

*Weight and nutrition*, 130

Monoresistance, 33-34

Moxifloxacin, 35, 46, **82-83**, 102, 106, 155, 189, 241

See also *Fluoroquinolones*

Musculoskeletal adverse effects, 75, 79, 82, 86, 89, 134, **166-167**

*Tendonitis and tendon rupture*, 79, 82, 134, **166-167**, 207, 208, 247, 250

Mutations, 11, **12**, 27, 36, 44, 46, 234, 235, 249

Myalgia, 148, **166-167**, 209

*Mycobacterium avium* complex (MAC), 13, 222

*Mycobacterium bovis*, 33, 34, 46, 108, **114**, 222

## N

Nausea, 60, 72, 79, 80, 82, **147-149**, 156, 159, 165, 247

Nephrotoxicity, 59, 63, 77, 93, **165-166**

*Electrolyte loss*, 44, 59, 63, 84, 93, 148, 158, 161, **165-166**

*Prevention and monitoring*, 38, 59, 63, 77, 93, 118, **165**

Neurotoxicity, 67, 70, 72, 75, 77, 79, 80, 82, 93, 106, 133, 134, 136, **158-164**

New drug-resistant TB case, 3

Newborn, 110-112

Nonsteroidal anti-inflammatory drugs (NSAIDs) 148, 158, 159, 166

Nontuberculous mycobacteria (NTM), 25, 27, 202, 222

Nutrition, 21, 100, **130-131**, 132, 147, 180, **181**

## O

Obesity, 58, 62, 68, 76, 86, 92, 106, 120,

Ophthalmic toxicity, ix, 37, 45, 68, 75, 80, 81, 89, 104, 117, 134, 143, 151, **163-164**

Optic neuropathy, 37, 45, 68, 75, 81, 163

*Prevention and monitoring of*, 133, 143

*Retrobulbar neuritis*, 68, 164

*Uveitis*, 89, 133, 163, 164

Orders to appear and comply, 197

Orders to isolate or detain, 197

Ototoxicity, ix, 38, 59, 63, 77, 93, 105, 118, 134, 143, 146, **162-163**, **246**

*Auditory*, ix, 59, 63, 77, 93, 105, 118, 134, 143, 146, **162-163**, **246**

*Vestibular*, 59, 63, 77, 93, 105, 118, 143, **162-163**, 180, 246

## P

Para-Aminosalicylate (PAS), 24, 35, 37, 39, 44, 46, 47, 48, 52, **84-85**, 97, 102, 105, 106, 109, 118, 122, 133, 134, 147, 149, 153, 167, 189, 206, 207, 233, 237, 241, 245

Paradoxical reaction, 96, 99

Partners In Health, 218, 220

Patient assistance programs (PAPs), **189**, 248

Patient education, 131, 172, 174, **176-177**, 198, 243

Patients' Charter for Tuberculosis Care 2, 221

Pediatrics, 113-122

*Cultures*, 113-114

*Treatment*, 114-122

*Drug administration*, 116

*Drug dosing*, 119-122

Pericarditis, 96

Peripheral neuropathy, 45, 67, 74, 75, 80, 81, 100, 134, **158-159**

Pharmacokinetics, 58-93, **240-242**

Phototoxicity, 64, 79, 87, 95, 151, **152**

Polymerase Chain Reaction (PCR), 27, **234**, 249

Pregnancy, 58-93, **108-112**, 128, 147, 158

*Breastfeeding*, 58-93, **110**, 111

*Congenital TB*, **110-111**

*Infection control*, 110

*Management of newborn*, 110-112

*Prevention of infection*, 111-112

*Teratogenicity*, 109

Previously treated TB case, 3

Pre-XDR-TB, 4

Primary drug resistance, 3

Pruritus, 64, 91, **151-2**, 156

Psycho/social needs, 99, 100, 159, 172, **174-175**

Psychosis, 67, 131, **160**

Pyrazinamide (PZA), 10, 11, 12, 13, 24, 26, 33, 34, 35, 36, 37, 39, 40, 41, 43, 46, 51, 52, **86-87**, 97 102, 106, 108, 109, 114, 130, 134, 152, 153, 155, 165, 166, 204, 206, 207, 209, 223, 233, 234, 236, 241, 250, 251

Puentes de Esperanza, 3

## Q

QuantiFERON®-TB Gold (QFT-G), 22, 202, 203, 204

QuantiFERON®-TB Gold In Tube (QFT-GIT), 202, 204

## R

Radiograph, chest, 18, 19, 50, 110, 111, 115, 135, **137**, 208, 210, 250

Rash, maculopapular, 60, 64, 86, 89, 91, **151-152**

Rechallenge (see *Dermatologic and Hypersensitivity Reactions*)

Red cell aplasia, 155, **157**

Relapse, 28, **50-51**

Renal failure (managing TB in presence of), 58-93, **104-107**

Reporting requirements, 196

Respiratory symptoms, **132**, 135

Retrobulbar neuritis, 68, 164

Rifabutin, ix, 13, 24, 33, 36, 46, **88-89**, 97, 100, 109, 133, 134, 152, 155, 163, 164, 166, 233, 241

Rifampin (RIF), vii, 2, 4, 7, 10, 11, 12, 13, 22, 24, 26, 27, 30, 33, 34, 35, 36, 37, 39, 40, 46, 49, 51, 52, 75, **90-91**, 97, 98, 100, 102, 106, 108, 109, 111, 114, 119, 134, 152, 153, 154, 155, 156, 157, 204, 206, 209, 210, 223, 233, 234, 235, 236, 238, 239, 241, 249, 251

Risk assessment, **18**, 186

Risk factors, **19-21**

## S

Scrofula, 96

Secondary drug resistance, 3

Second-line drugs, 3, 35, 37-40, 44, 48, 52

Seizure, 67, 72, 74, 136, **161**, 249

Side effects (see Adverse Reactions)

Sputum induction, 113, 180, 223, 247

Steroid (see Corticosteroid)

Stevens-Johnson syndrome, 67, 154, 156

Stop TB, 220, 221

Strain typing, **28**, 224, 226, 228, 231

Strain W, 42, 74

Streptomycin (SM), 10, 11, 12, 24, 33, 35, 39, 58, 59, 63, 77, **92-93**, 105, 106, 109, 121, 152, 153, 155, 156, 162, 163, 188, 223, 236, 237, 238, 239, 240, 242, 246

Studies of MDR-TB outcomes, 41-43

Substance abuse, 13, 99, 100, 128, **131**, 159, 174

Suicidal ideation, 67, 131, 159, **160**, 247

Surgery, 37, 39, 40, **49**, 97, 130

Susceptibility testing (see Laboratory Diagnosis)

## T

TB Net, 3, 182, 187, 220

Tendonitis / tendon rupture, 79, 82, 134, **166-167**, 207, 208, 247, 250

Teratogenicity, 109

Therapeutic drug monitoring, ix, **136**, **240**, 249

Third-line drugs, 35, 37, 38, 39, 40, **45**, 47, 136, 244

Thrombocytopenia, 89, 91, **155**, 157

Thyroid, 47, 70, 71, 84, 117, 133, 134, 152, 158, 160, 166, **167**

Tinnitus, 162-163, 246

Toxic epidermal necrolysis (TEN), 154, 156

Toxicity (see Adverse Reactions)

Transmission, 28, 177, 183, 184, 186-187, 194, **204-205**, 209, 210, 250

Transportation of patients, 179, 184, **186**

Treatment,

- Alternative or third-line drugs*, 35, 37, 38, 39, 40, **45**, 47
- Aminoglycosides and polypeptides*, **44**
  - See also Amikacin, Capreomycin, Kanamycin, and Streptomycin
- Cross-resistance*, 33, 36, 45, **46**
- Escalation of dosages (drug ramping)*, **48**, 70, 121, 149
- Experts, consultation with*, 25, 47, 49, **53**
- Failure*, 32, 41, **49-50**
- Fluoroquinolones*, 12, 35, 38, **44**, 46, 78-79, 82-83, 102, 109, 117, 118, 134, 149, 158, 166, 168, 188, 209, 245

*Guidelines for management*, 36

*Mono-resistant M. tuberculosis, EMB, PZA, or SM*, 33-34

*Mono-resistant M. tuberculosis, INH*, 33-34

*Mono-resistant M. tuberculosis, RIF*, 33-34

*Oral second-line drugs*, 44

*Pediatrics (see Pediatrics)*

*Regimen, administration of*, 47-48

*Regimens for monoresistance*, 33-34

*Regimens for multidrug resistance*, 35-40

*Re-treatment options*, 51

*Selection and dosing of individual drugs*, 44-45

*Starting an expanded regimen*, 32, 51, 52

*Surgery, role of*, 37-40, **49**

Treatment of contacts (see Contacts, Managing)

T-SPOT.TB, 22, 202, 204

Tuberculin skin test (TST), 22, 51, 112, 187, 202-203, 210, 250

## U

United States, epidemiology of drug-resistant TB, 4, 5, 7-9

Urticaria (see Dermatologic and Hypersensitivity Reactions)

Uveitis (see Ophthalmic Toxicity)

## V

Vasculitis, 75, 157

VersaTREK, 26, 233, 239

Vestibular toxicity, 59, 63, 77, 93, 105, 118, 143, **162-163**, 180, 246

Vision screening, 69, 89, 117, **133**, **143**, 163-164

Vomiting, 60, 72, 132, 134, **147**, 148, 150, 156, 165

## W

Weight / nutrition, 21, 100, **130-131**, 132, 147, 180, **181**

Wild-type strain, 11, 25, 233

Window prophylaxis, x, 184-185, 204-205, **210**

## X

XDR-TB (Extremely Drug-Resistant TB), vii, **4**, 5, 6, 7, 9, 22, **39**, 189, 251-253

X-ray, Chest (See Radiograph, Chest)